These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 4747574)

  • 1. Effect of combination treatment with adriamycin and methotrexate on the survival time of leukemic (L 1210) mice.
    Miyakawa A; Padarathsingh M; Vadlamudi S; Goldin A
    Chemotherapy; 1973; 19(1):38-46. PubMed ID: 4747574
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytotoxicity of adriamycin combined with methotrexate against L1210 leukemia in mice.
    Valeriote F; Vietti T; Coulter D
    J Natl Cancer Inst; 1980 Apr; 64(4):801-5. PubMed ID: 6928994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of adriamycin with DNA-adriamycin complex in chemotherapy of experimental tumors and metastases.
    Atassi G; Duarte-Karim M; Tagnon HJ
    Eur J Cancer (1965); 1975 May; 11(5):309-16. PubMed ID: 1157820
    [No Abstract]   [Full Text] [Related]  

  • 4. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.
    Avery TL; Roberts D
    Cancer Res; 1977 Mar; 37(3):678-83. PubMed ID: 837368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination chemotherapy in sequence for the treatment of L1210 leukemia.
    Roberts D; Hilliard SL
    Cancer Res; 1978 Aug; 38(8):2317-20. PubMed ID: 667827
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of day of dosage omission on survival time in the regularly scheduled methotrexate (NSC-740) treatment of leukemia L1210.
    Straus MJ; Goldin A
    Cancer Chemother Rep; 1972 Feb; 56(1):25-30. PubMed ID: 5030806
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of adriamycin with the DNA-adriamycin complex in chemotherapy of L1210 leukemia.
    Atassi G; Tagnon HJ
    Eur J Cancer (1965); 1974 Jul; 10(7):399-403. PubMed ID: 4457343
    [No Abstract]   [Full Text] [Related]  

  • 8. Potentiation of the antitumor activity of methotrexate by concurrent infusion of thymidine.
    Semon JH; Grindey GB
    Cancer Res; 1978 Sep; 38(9):2905-11. PubMed ID: 679199
    [No Abstract]   [Full Text] [Related]  

  • 9. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).
    Woodman RJ; Cysyk RL; Kline I; Gang M; Venditti JM
    Cancer Chemother Rep; 1975; 59(4):689-95. PubMed ID: 1175163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Studies on the mechanisms of resistance to methotrexate--with special emphasis on the change of nucleotide pools].
    Nobori T; Shimizu N; Ohkubo T; Kawasaki H; Sako T; Komada M; Hirota H; Kamiya H; Sakurai M
    Nihon Ketsueki Gakkai Zasshi; 1986 May; 49(3):661-9. PubMed ID: 3766065
    [No Abstract]   [Full Text] [Related]  

  • 11. [Possibility of utilizing lymphatic leukemia L1210 as a first screening model in the primary selection of new antitumor antibiotics].
    Shorin VA; Bazhanov VS
    Antibiotiki; 1974 Aug; 19(8):679-84. PubMed ID: 4455117
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia.
    Schmid FA; Hutchison DJ
    Cancer Chemother Rep; 1972 Aug; 56(4):473-81. PubMed ID: 5081590
    [No Abstract]   [Full Text] [Related]  

  • 13. Combination chemotherapy of L1210 leukemia with platinum compounds and cyclophosphamide plus other selected antineoplastic agents.
    Glae GR; Atkins LM; Meischen SJ; Smith AB; Walker EM
    J Natl Cancer Inst; 1976 Dec; 57(6):1363-6. PubMed ID: 187805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined interferon--antimetabolite therapy of murine L1210 leukemia.
    Slater LM; Wetzel MW; Cesario T
    Cancer; 1981 Jul; 48(1):5-9. PubMed ID: 6165457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA--anthracycline complexes. I. Toxicity in mice and chemotherapeutic activity against L1210 leukemia of daunorubicin--DNA and adriamycin--DNA.
    Deprez-de Campeneere D; Trouet A
    Eur J Cancer (1965); 1980 Aug; 16(8):981-6. PubMed ID: 7439227
    [No Abstract]   [Full Text] [Related]  

  • 16. Differential cell permeability and the basis for selective activity of methotrexate during therapy of the L1210 leukemia.
    Sirotnak FM; Donsbach RC
    Cancer Res; 1973 Jun; 33(6):1290-4. PubMed ID: 4718678
    [No Abstract]   [Full Text] [Related]  

  • 17. Pre- and co-treatment with xanthophyll enhances the anti-leukemic activity of adriamycin.
    Lee KH
    J Photochem Photobiol B; 2008 Sep; 92(3):175-9. PubMed ID: 18653355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. X.
    Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
    Cancer Chemother Rep 2; 1972 Nov; 3(1):1-69. PubMed ID: 4660732
    [No Abstract]   [Full Text] [Related]  

  • 19. [Neuroleukemia in mice with leukemia L1210 treated with methotrexate].
    Petrov SA
    Gematol Transfuziol; 1989 Nov; 34(11):46-50. PubMed ID: 2612863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness of combined action of vitamins A, E and C and cyclophosphane or adriamycin on growth of transplanted tumors in mice].
    Mosienko VS; Khasanova LT; Sukolinskiĭ VN; Morozkina TS
    Eksp Onkol; 1990; 12(3):55-7. PubMed ID: 2344827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.